Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (August 2022)
27 slides from Cognition Therapeutics's investor presentation, Aug 29, 2022
Slide 1: Developing disease-modifying medicines for degenerative disorders
Developing disease- modifying medicines for degenerative disorders August 2022
Slide 2: Forward-looking statements
2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but
Slide 3: Who We Are
3 Who We Are Targeting unmet needs in age-related degenerative disorders of the central nervous system and retina such as Alzheimer’s disease, dementia with Lewy bodies (DLB), dry age-related macular degeneration (dry AMD), and Parkinson’s disease Functionally distinct therapeutic approach focused o
Slide 4: Pipeline
4 Product Candidate Target Indication Preclinical Phase 1 Phase 2 Phase 3 Funding CT1812 SEQUEL Mild-moderate AD $3.3M CT1812 SHINE Mild-moderate AD $30M CT1812 SHIMMER DLB $30M CT1812 START Early-stage AD $81M CT1812 Dry AMD CT2168 Synucleinopathies † CT2074 Dry AMD Pipeline † including Parkinson’s
Slide 5: Grants Continue to Provide Funding
5 Clinical Study Total Awarded Remaining (yet to be drawn down) START (early AD) $ 81 Million $ 65.1 Million SHINE (mild/mod AD) $ 30.5 Million $ 11 Million SHIMMER (DLB) $ 29.5 Million $ 20.5 Million SEQUEL (qEEG in AD) $ 3.3 Million $ 0.4 Million $ 144.3 Million $ 97 Million Approximately 50% of R
Slide 6: Key Upcoming Milestones & Expected Timing
6 2021 2022 2023 Completing • PK • Human AME • SEQUEL Conducting • SHINE (cohort 2) • Phase 2 in DLB • Phase 2 with ACTC • Phase 2 in dry AMD • IND-enabling studies for research compounds Key Upcoming Milestones & Expected Timing Completed ✓ SNAP ✓ SPARC ✓ SHINE (cohort 1) Completing • SHINE (cohort
Slide 7: Review of CT1812 for the Treatment of Alzheimer's Disease
Review of CT1812 for the Treatment of Alzheimer’s Disease Cognition Lead Program:
Slide 8: Alzheimer's Disease Market Overview
8 • Approx. 6.2 million individuals in United States are afflicted with Alzheimer’s disease1 - Approximately 35 million people worldwide2 - Prevalence expected to double by 20501 • Direct healthcare costs for patients with Alzheimer’s and other dementias is estimated to exceed $300 billion in the Un
Slide 9: CT1812: A Synaptoprotective Approach to Alzheimer's Disease
9 • CT1812 penetrates the blood-brain barrier (BBB) and binds selectively to the σ-2 receptor • By modulating σ-2, CT1812 displaces and prevents oligomers from binding to neurons and clears them into CSF • Prevents synaptotoxicity and facilitates restoration of neuronal function • CT1812 mimics the
Slide 10: Evidence of Target Engagement: SNAP
10 Evidence of Target Engagement: SNAP (COG0104) First evidence of target engagement in humans, mirrors preclinical findings, corroborating our mechanism of action …and now in people with Alzheimer’s disease CT1812 oligomer receptor complex PGRMC1 σ-2 receptor complex TMEM97 This displacement can be
Slide 11: SHINE interim analysis yields promising evidence
11 • Trend towards slower cognitive decline in CT1812-treated vs placebo-treated participants as measured by ADAS-Cog 11 Cognitive & Biological Outcomes • Statistically significantly lower Aβ protein (p=0.017) in treated vs placebo patients • Additional analyses on p-tau, synaptic and AD-related pro
Slide 12: Biomarkers Associated with Alzheimer's Pathology Normalized by CT1812
12 Biomarkers Associated with Alzheimer’s Pathology Normalized by CT1812 Biomarkers normalized by CT1812 Most Highly Represented Pathways Pharmacodynamic Biomarkers of CT1812 Discovered M4 Synapse/Neuron M3 Oligo/Myelination M1 Synapse/Neuron M21 MHC Complex/Immune M42 Matrisome M17 Transcription M1
Slide 13: SPARC (COG0105) Results
13 1° Endpoints: • Impact of CT1812 on synaptic density as measured by SV2A; safety and tolerability Results: • No difference in synaptic density in CT1812- or placebo-treated vs baseline • Trend towards preservation of brain volume (composite) in CT1812- vs placebo-treated - Statistically significa
Slide 14: Proteomic Data from SPARC Shows Effect on Disrupted Alzheimer's Processes
14 • 37 proteins in CSF were significantly (p<0.05) normalized towards control with CT1812 compared to placebo • These proteins are involved in key pathways disrupted in Alzheimer’s: autophagy, inflammation, synaptic function - Include previously well-characterized biomarkers of Alzheimer's disease,
Slide 15: Biomarkers of CT1812 Identified
15 -2.50 -2.00 -1.50 -025 000 025 050 075 200 250 300 350 PLXDC2 PRSS23 PCYOX1 F13A1 RNASE6 RNASE4 VASN SOD3 ANG WFIKKN2 SLPI MERTK APOL1 LRP1 PLD3 CD5L IGLV8-61 IGLV3-25 IGLV3-16 ARG1 B2M SMOC1 C1R IGHD IGHM COL6A2 VCAN ADARB1 CALB2 LAMP2 LAMP1 IGFBP2 OLFML3 ALDOC SPON1 CHI3L1 DTD1 log2 abundance I
Slide 16: SEQUEL (COG0202)
16 • Principal investigator: E. Vijverberg, MD, PhD; neurologist at Vumc Alzheimer’s Center • Single-site quantitative EEG study in patients with mild-to-moderate AD • Two group cross over design • Objective: evaluate the efficacy of CT1812 in restoring synaptic function through quantitative EEG, as
Slide 17: START Trial in Early Alzheimer's Disease
17 • Phase 2 efficacy study, powered to show change in cognition: slowing or halting cognitive decline • Enrollment expected to commence 2H 2022 • Enrolling 540 participants with early Alzheimer’s disease at 50-60 U.S. sites • Supported by $81M Grant from NIA - Grant awarded in collaboration with AC
Slide 18: Synucleinopathies
Synucleinopathies Disorders such as DLB and Parkinson’s disease that are characterized by deposits of α-synuclein aggregates (called Lewy bodies) that disrupt key cellular processes Cognition Pipeline:
Slide 19: Synucleinopathies are 2nd only to AD in Prevalence
19 • In the U.S., approximately 13 million people have a form of dementia1 - Dementia with Lewy bodies (DLB): 1.4 million - PD: 1 million • Direct healthcare costs: - DLB: $31.5 billion2 - PD: $25 billion3 Synucleinopathies are 2nd only to AD in Prevalence Parkinson's Disease DLB Alzheimer's Disease
Slide 20: σ-2 Modulators May be Disease Modifying in Synucleinopathies
20 σ-2 Modulators May be Disease Modifying in Synucleinopathies Cellular evidence that σ-2 modulators have a beneficial impact α-synuclein oligomer-induced trafficking deficits (red) are reversed by Cognition drug (black) Cognition antagonists block the binding / internalization of α-synuclein oligo
Slide 21: DLB Phase 2 SHIMMER Study
21 • Principal investigator: James E. Galvin, MD, MPH, professor of neurology and director of the Comprehensive Center for Brain Health • Phase 2 trial ongoing - Participant dosing underway • U Miami and 20+ academic sites • Archived DLB R&D educational symposium available: https://ir.cogrx.com DLB
Slide 22: Dry Age-related Macular Degeneration
Dry Age-related Macular Degeneration Cognition Pipeline:
Slide 23: Rationale for σ-2 Modulators in Dry AMD
23 σ-2 receptors • Expression: in RPE cells, retinal ganglion cells, photoreceptors in retina • Biology: Regulates autophagy, protein trafficking, lipid metabolism dysregulated in AMD • Target validation: TMEM97 knockdown is protective • Human genetics: Linked to dry AMD σ-2 receptor modulators • No
Slide 24: σ-2 Receptor Modulators Prevent Deficits in Trafficking / Degradation of POS
24 • Aβ oligomers and oxidative stress cause lysosomal deficits in capacity to traffic & degrade photoreceptor outer segments (POS) cargos in RPE cells • σ-2 receptor modulators from 3 chemically distinct series rescued these deficits Results: σ-2 Receptor Modulators Prevent Deficits in Trafficking
Slide 25: Planned Phase 2 in Dry AMD
25 Genetic, Clinical Biomarker and Preclinical Data Support Moving Forward with CT1812 for dAMD Assessments such as: Change in GA lesion Low luminance visual acuity (LLVA) Best-corrected visual acuity (BCVA) Study Drug Administration Screening: Age: ≥ 50 Diagnosis of dry AMD BCVA ≥ 24 letters (ETDRS
Slide 26: Financial Position
Financial Position Financials as of June 30, 2022 • Cash and Cash Equivalents: $45.8 million • Proceeds raised from IPO: $52.0 million • Expected cash runway into 2H 2023 NIA funding for CT1812 studies as of June 30, 2022 • Preclinical through Phase 2 studies $168.4 million • Approximate funding use
Slide 27: Thank You
Thank You Andy Einhorn Interim CFO 973-879-8240 aeinhorn@cogrx.com Lisa Ricciardi President & CEO 917-658-5789 lricciardi@cogrx.com
Cognition Therapeutics — Investor Presentation (August 2022) on 6ix